Atopic Dermatitis Treatment: Rich Portfolio of Therapeutic Options Shaping the Future

Currently, a variety of candidate drugs for the treatment of atopic dermatitis are being tested in various clinical trials, with some showing positive results. Any drug approved with increased safety and efficacy is expected to cause significant changes in the overall atopic dermatitis market.

Find More
GSK and iTeos Alliance Boosts Belrestotug Prospects in TIGIT Space

One of the most notable advancements in the anti-TIGIT landscape was the collaboration between GlaxoSmithKline and iTeos Therapeutics, around the time of peak TIGIT mania in 2021, culminating in a USD 625 million deal for the anti-TIGIT monoclonal antibody Belrestotug (EOS-448)

Find More
The Rise of Sleep Tech Devices: Unlocking Better Sleep

As per the latest assessment by DelveInsight, the global sleep tech devices market was valued at ~USD 17 billion in 2023, growing at a CAGR of 17.31% during the forecast period from 2024 to 2030 to reach ~USD 44 billion by 2030.

Find More
Phathom Secures Dual FDA Approvals for Voquezna Following Impurity Setback

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.

Find More
The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Find More
Rehabilitation Equipment Market Analysis
Evaluating the Growing Role of Rehabilitation Equipment in Revitalizing Lives and Improving the Treatment Outcome

Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone a remarkable evolution over the years, propelled by the rising demand and their potential to improve patient outcomes and restore quality of life. From rudimentary tools and manual therapies to the present-day sophisticated, technolog...

Find More
Servier’s Tibsovo Opens The Door To A New Era In The Battle Against Myelodysplastic Syndromes

Servier’s Tibsovo has received FDA approval for patients diagnosed with R/R myelodysplastic syndromes that exhibit an IDH1 mutation.

Find More
Roche’s Vabysmo Third US Approval Spiced Up the Battle With Regeneron and Bayer’s Eylea

Roche’s Vabysmo secures new FDA nod for retinal vein occlusion treatment, intensifying competition with Regeneron and Bayer’s Eylea.

Find More
Energy-based Aesthetic Devices Market Outlook
Glowing Prospects: Energy-Based Aesthetic Devices Market Outlook

The Energy-Based Aesthetic Devices market stands at the forefront of the evolving landscape of cosmetic treatments, offering a comprehensive range of solutions for individuals seeking non-invasive and minimally invasive procedures to enhance their appearance. Over the past few years, intense advancements in technol...

Find More
Coherus and Junshi’s Loqtorzi: First-ever Chinese PD-1 Inhibitor and Nasopharyngeal Carcinoma Treatment

Coherus and Junshi received FDA approval for Loqtorzi, marking significant milestone as first-ever nasopharyngeal carcinoma treatment.

Find More